Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Resectable Stage II-IIIB NSCLC

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Unresectable Non-small Cell Lung Cancer

Lung Neoplasms, Mesothelioma, Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

SCLC, Extensive Stage

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Extensive Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

EGFR Positive Non-small Cell Lung Cancer

Small Cell Lung Cancer Recurrent

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Advanced Non-small-cell Lung Cancer

Small Cell Lung Carcinoma

Adenocarcinoma of Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Advanced NSCLC With EGFR Mutation

Adenocarcinoma of Lung

Small Cell Lung Carcinoma

Small Cell Lung Cancer Extensive Stage

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Adenocarcinoma of Lung

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Non-small Cell Lung Cancer Metastatic

Clinical Trials

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

TARGET-01

A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.

FLAME-1

Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer

A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer

L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLC

A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer

Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC

Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)

AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer

Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

ASTEROID

Artemis

Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer

Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations

AvaTa

Atezolizumab

Study of Lorlatinib in ROS1 Rearranged NSCLC

Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

An Exploratory Study of Herombopag for Thrombocytopenia Induced by Chemotherapy Combined With Immunotherapy in NSCLC

Tislelizumab as Cross-line Treatment for Advanced NSCLC

CAMERA

Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

MWA in NSCLC

Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation

Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer

SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer

PIN

Microwave Ablation in Ground Glass Nodules

Geber

EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease